Additional file 1: of Increasing incidence associated with herpes zoster infection in British Columbia, Canada

Table S1. Description of the datasets used for data linkage. Table S2. Definitions for immunosuppression. Table S3. Crude and Age-Sex Standardized Incidence Rate and 95 % Confidence Interval by Year. Table S4. Rate Ratio of Age-Sex Standardized Mean Annual Incidence Rate and 95 % Confidence Interval with Bonferroni Correction for Multiple Comparison. Table S5. Rate Ratio on Herpes Zoster Incidence and 95 % Confidence Interval Using a Regression Model. (DOCX 28 kb

Additional file 1: of Parents and adolescents preferences for asthma control: a best-worst scaling choice experiment using an orthogonal main effects design

Illustration of choice options for each task and hypothetical best and worst choices for three respondents. (DOCX 19 kb

The estimated monetary benefit of each hypothetical intervention assuming different scenarios for effectiveness of these interventions in reducing smoking rates (intervention I), progression of disease (intervention II), and exacerbation rates (intervention II).

<p>The estimated monetary benefit of each hypothetical intervention assuming different scenarios for effectiveness of these interventions in reducing smoking rates (intervention I), progression of disease (intervention II), and exacerbation rates (intervention II).</p

The projected increase in the prevalence of COPD in Canada in men (A) and women (B) across disease severities.

<p>The projected increase in the prevalence of COPD in Canada in men (A) and women (B) across disease severities.</p

The projected changes in quality adjusted life years lost related to COPD in Canada in men (A) and women (B).

<p>The projected changes in quality adjusted life years lost related to COPD in Canada in men (A) and women (B).</p

Key input parameters in the model.

a<p>rates were calculated based on relative risk of mortality per smoking status <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746-Gamble1" target="_blank">[25]</a>, 2002 Canadian life tables, and 2010 mortality estimates, Statistics Canada (See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746.s002" target="_blank">Appendix S2</a>).</p>b<p>were estimated based on the symptom rates among smokers, previous smokers, and never smokers reported by Mannino et al <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746-Mannino2" target="_blank">[36]</a> for men and women and also proportion of patients without COPD reported by Buist et al <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746-Buist1" target="_blank">[9]</a>.</p>c<p>Estimated based on the reported rates for men and women in Buist et al <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746-Buist1" target="_blank">[9]</a> (See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746.s002" target="_blank">Appendix S2</a>).</p>d<p>Estimated based on COPD specific mortality rate of 30.4 per 10,000 (Camp et al <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746-Camp1" target="_blank">[12]</a>) and probabilities of major exacerbations.</p>e<p>Estimated based on progression rates in Hoogendoorn et al <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746-Hoogendoorn4" target="_blank">[31]</a> (See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746.s002" target="_blank">Appendix S2</a>).</p>f<p>these weights are EQ-5D Scores.</p>g<p>Costs in in Mannino et al <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746-Mannino2" target="_blank">[36]</a> were multiplied by 1.155 to reflect the changes in Canadian Consumer Price Index (CPI) between 2002 and 2011.</p>h<p>Estimated based on proportion of major/minor exacerbations used in Spencer et al <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046746#pone.0046746-Spencer1" target="_blank">[13]</a>.</p

The projected changes in the costs related to COPD in Canada in men (A) and women (B) at various discount rates.

<p>The projected changes in the costs related to COPD in Canada in men (A) and women (B) at various discount rates.</p

Outcomes of hypothetical interventions.

<p>I. Decreasing smoking start rate (by testing for COPD predisposition in early smokers).</p><p>II. Decreasing progression rates (by access to new pharmacogenomic agents).</p><p>III. Decreasing exacerbations (by prediction of exacerbators).</p

The results of one-way sensitivity analyses on the total cost related to COPD in Canada over the next 25 years.

<p>The results of one-way sensitivity analyses on the total cost related to COPD in Canada over the next 25 years.</p